Details of Disease

General Information of Disease (ID: DIS56IFV)

Disease Name	Pheochromocytoma
Synonyms	pheochromocytoma, susceptibility to; phaeochromocytoma; pheochromocytoma
Disease Class	5A75: Adrenomedullary hyperfunction
Disease Hierarchy	DISEG3D2: Benign neoplasm of adrenal gland DISP9K7L: Hereditary pheochromocytoma-paraganglioma DIS56IFV: Pheochromocytoma
ICD Code	ICD-11 ICD-11: 5A75 ICD-10 ICD-10: E27.5 Expand ICD-11 '5A75 Expand ICD-10 'E27.5 Expand ICD-9 194.0,227.0,255.6
Disease Identifiers	MONDO ID MONDO_0008233 MESH ID D010673 UMLS CUI C0031511 OMIM ID 171300 MedGen ID 18419 HPO ID HP:0002666

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Iobenguane Sulfate I-131	DME1OHR	Approved	Small molecular drug	[1]
Metyrosine	DMBYCU0	Approved	Small molecular drug	[2]
Phenoxybenzamine	DM8KSQH	Approved	Small molecular drug	[3]
Phentolamine	DMXYJOB	Approved	Small molecular drug	[4]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Metaiodobenzylguanidine I-131	DMNST69	Phase 2	Small molecular drug	[5]
EO2401	DMCN3UU	Phase 1/2	Vaccine	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 45 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
DBH	TTYIP79	Limited	Altered Expression	[7]
ACVR1	TTJNBQA	Strong	Altered Expression	[8]
ACVR1B	TTPKHTZ	Strong	Altered Expression	[8]
ADCYAP1	TTW4LYC	Strong	Biomarker	[9]
AGTR2	TTQVOEI	Strong	Altered Expression	[10]
CALCRL	TTY6O0Q	Strong	Biomarker	[11]
CGB3	TTUH273	Strong	Biomarker	[12]
COMT	TTKWFB8	Strong	Biomarker	[13]
CS	TTZA6B3	Strong	Altered Expression	[14]
DDC	TTN451K	Strong	Biomarker	[13]
ENPEP	TT9PBIL	Strong	Biomarker	[15]
EPAS1	TTWPA54	Strong	Genetic Variation	[16]
EPOR	TTAUX24	Strong	Biomarker	[17]
FGF21	TTQ916P	Strong	Biomarker	[18]
GALR2	TTBPW3J	Strong	Altered Expression	[19]
GAP43	TTSGLN5	Strong	Biomarker	[20]
GCGR	TT9O6WS	Strong	Altered Expression	[21]
GHRHR	TTG4R8V	Strong	Altered Expression	[22]
GHRL	TT1OCL0	Strong	Altered Expression	[23]
HCRTR1	TT60Q8D	Strong	Biomarker	[24]
HSD17B13	TTDJYZR	Strong	Altered Expression	[25]
HTR4	TT07C3Y	Strong	Altered Expression	[26]
KCNJ5	TTEO25X	Strong	Altered Expression	[27]
MAOA	TT3WG5C	Strong	Biomarker	[13]
MAOB	TTGP7BY	Strong	Biomarker	[13]
NPY	TT64REZ	Strong	Altered Expression	[9]
PCSK2	TT46F0P	Strong	Altered Expression	[28]
PDE11A	TTTWC79	Strong	Genetic Variation	[29]
QPCT	TTJ7YTV	Strong	Biomarker	[30]
RGS6	TTJ96M8	Strong	Biomarker	[31]
RPS6KB2	TTMVQXO	Strong	Altered Expression	[32]
SCARB1	TTRE324	Strong	Genetic Variation	[33]
SLC18A2	TTNZRI3	Strong	Altered Expression	[34]
SLC6A2	TTAWNKZ	Strong	Altered Expression	[35]
SORD	TTLSRBZ	Strong	Genetic Variation	[36]
SSTR1	TTIND6G	Strong	Biomarker	[37]
SSTR5	TT2BC4G	Strong	Altered Expression	[37]
STMN1	TT7W5OT	Strong	Biomarker	[38]
TH	TTUHP71	Strong	Altered Expression	[39]
UCP1	TTI12YJ	Strong	Biomarker	[40]
UTS2	TTERU0T	Strong	Biomarker	[41]
UTS2R	TTW5UDX	Strong	Altered Expression	[41]
VIPR1	TTCL30I	Strong	Altered Expression	[9]
VIPR2	TT4O5P0	Strong	Altered Expression	[42]
ADM	TTV14YH	Definitive	Biomarker	[43]
------------------------------------------------------------------------------------


⏷ Show the Full List of 45 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC17A6	DT5LHCR	Strong	Altered Expression	[44]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
HSD17B7	DEDMWFX	Strong	Altered Expression	[25]
MT1A	DE5ME8A	Strong	Genetic Variation	[45]
------------------------------------------------------------------------------------

This Disease Is Related to 72 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
DMBT1	OTVNU9D9	Limited	Biomarker	[46]
SCTR	OTC80IMR	Limited	Altered Expression	[47]
KIF1B	OTI1XQTO	Moderate	Autosomal dominant	[48]
ACO1	OT2VUR7L	Strong	Genetic Variation	[49]
ADIPOR1	OT65ZFZN	Strong	Altered Expression	[50]
AIP	OTDJ3OSV	Strong	Genetic Variation	[29]
ARHGEF1	OTXU4HBW	Strong	Altered Expression	[51]
ASCL1	OTI4X44G	Strong	Altered Expression	[52]
CBX4	OT4XVRRF	Strong	Altered Expression	[28]
CHGA	OTXYX5JH	Strong	Biomarker	[53]
CHGB	OT7SAQT2	Strong	Biomarker	[54]
CLDN10	OT2CVAKY	Strong	Biomarker	[55]
CNTN4	OTULXVE0	Strong	Altered Expression	[56]
CTNNBL1	OT6KLHPA	Strong	Biomarker	[57]
CUL4A	OTTBV70J	Strong	Biomarker	[58]
DHRS11	OTU3J0ZL	Strong	Altered Expression	[25]
DIRAS3	OT3XHLQA	Strong	Biomarker	[59]
DLST	OTBDF9HJ	Strong	Genetic Variation	[60]
ELOA	OTOQTF5K	Strong	Genetic Variation	[61]
ELOB	OTZ3X84T	Strong	Genetic Variation	[61]
EMP3	OTODMJ1D	Strong	Posttranslational Modification	[62]
ERV3-1	OT4CW64T	Strong	Altered Expression	[63]
FARP1	OTL1EBTM	Strong	Altered Expression	[51]
FH	OTEQWU6Q	Strong	Biomarker	[64]
FNDC3A	OTUX3S2I	Strong	Biomarker	[28]
FSIP1	OTYLL6GM	Strong	Biomarker	[25]
GIPC1	OTXLVCPJ	Strong	Altered Expression	[65]
GPR143	OTWUA2AV	Strong	Altered Expression	[66]
GPR68	OT1NXSMN	Strong	Altered Expression	[67]
HPR	OTXSC9UB	Strong	Altered Expression	[68]
HYLS1	OT3SW5UC	Strong	Biomarker	[69]
ISL1	OTVNVKAX	Strong	Biomarker	[70]
KRT6B	OTBXJYHY	Strong	Altered Expression	[28]
MAML3	OTZFV53Z	Strong	Genetic Variation	[71]
MDH2	OT7364GY	Strong	Genetic Variation	[72]
MEN1	OTN6U6V0	Strong	Biomarker	[73]
MOS	OTNMQPFJ	Strong	Genetic Variation	[74]
MPZL2	OTKFNDUI	Strong	Genetic Variation	[75]
MYCL	OT1MFQ5U	Strong	Genetic Variation	[76]
MZB1	OT071TET	Strong	Altered Expression	[42]
NF1	OTC29NHH	Strong	Biomarker	[77]
NRTN	OT4PAKUY	Strong	Biomarker	[78]
PCDHGC3	OTDXTUMI	Strong	Posttranslational Modification	[79]
PDC	OT1UUVYY	Strong	Biomarker	[80]
PDE8B	OT4217NK	Strong	Genetic Variation	[29]
PDYN	OTEJ6430	Strong	Biomarker	[81]
PENK	OT8P3HMP	Strong	Altered Expression	[82]
PKD2	OTIXBU8H	Strong	Altered Expression	[28]
PLAGL1	OTZAO900	Strong	Altered Expression	[83]
PMCH	OT3D9SA4	Strong	Altered Expression	[84]
PMPCA	OT5X1G9Q	Strong	Genetic Variation	[33]
POU4F1	OTMHYGWQ	Strong	Altered Expression	[9]
PRDM2	OT8L7CGX	Strong	Biomarker	[85]
PTPRF	OTH5KF2D	Strong	Genetic Variation	[86]
RAB6A	OTLS86J5	Strong	Biomarker	[87]
RAMP2	OTGQXLH5	Strong	Altered Expression	[11]
RASSF5	OT6Q41I2	Strong	Biomarker	[88]
RBP3	OTIWM4GT	Strong	Biomarker	[89]
RNF41	OTN1DQOY	Strong	Altered Expression	[90]
RWDD3	OTE76DY5	Strong	Biomarker	[91]
SARDH	OTQ49Q27	Strong	Genetic Variation	[36]
SCG2	OTXWUQQL	Strong	Altered Expression	[28]
SDHA	OTOJ8QFF	Strong	Genetic Variation	[92]
SDHAF2	OT0UG9H5	Strong	Genetic Variation	[93]
SDHAF3	OTD2JO6B	Strong	Genetic Variation	[94]
SDHC	OTC8G2MX	Strong	Genetic Variation	[95]
SDS	OT5WTJ2M	Strong	Genetic Variation	[36]
SIM2	OT0QWHK4	Strong	Biomarker	[96]
SYP	OTFJKMO4	Strong	Biomarker	[97]
TDRD9	OTS4UBI8	Strong	Biomarker	[69]
MAX	OTKZ0YKM	Definitive	Autosomal dominant	[48]
TMEM127	OTYHUXC1	Definitive	Autosomal dominant	[48]
------------------------------------------------------------------------------------


⏷ Show the Full List of 72 DOT(s)

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6956).
3	Phenoxybenzamine FDA Label
4	Phentolamine FDA Label
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	ClinicalTrials.gov (NCT04187404) A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (Spencer). U.S. National Institutes of Health.
7	Catecholamine metabolism in paraganglioma and pheochromocytoma: similar tumors in different sites?.PLoS One. 2015 May 6;10(5):e0125426. doi: 10.1371/journal.pone.0125426. eCollection 2015.
8	Expression of activin A and its receptors in human pheochromocytomas.J Endocrinol. 2000 May;165(2):503-8. doi: 10.1677/joe.0.1650503.
9	Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival.Endocr Relat Cancer. 2010 Jun 25;17(3):637-51. doi: 10.1677/ERC-10-0109. Print 2010 Sep.
10	Immunohistochemical detection of angiotensin receptors AT1 and AT2 in adrenal tumors.Folia Histochem Cytobiol. 2008;46(1):51-5. doi: 10.2478/v10042-008-0006-7.
11	Expression and effect of adrenomedullin in pheochromocytoma.Ann N Y Acad Sci. 2006 Aug;1073:270-6. doi: 10.1196/annals.1353.030.
12	Severe arterial hypertension and hyperandrogenism in a boy: a rare case of catecholamine- and -HCG-secreting pheochromocytoma.J Pediatr Endocrinol Metab. 2019 Oct 25;32(10):1193-1197. doi: 10.1515/jpem-2019-0216.
13	Monoamine oxidase A down-regulation contributes to high metanephrine concentration in pheochromocytoma. J Clin Endocrinol Metab. 2012 Aug;97(8):2773-81. doi: 10.1210/jc.2012-1557. Epub 2012 May 8.
14	Alterations of respiratory chain complexes in sporadic pheochromocytoma.Front Biosci (Elite Ed). 2011 Jan 1;3(1):194-200. doi: 10.2741/e233.
15	PRECISION MEDICINE IN ADRENAL DISORDERS: THE NEXT GENERATION.Endocr Pract. 2017 Jun;23(6):672-679. doi: 10.4158/EP161716.RA. Epub 2017 Mar 23.
16	Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background.Cancers (Basel). 2019 May 28;11(6):743. doi: 10.3390/cancers11060743.
17	A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells.Cell Signal. 2007 Mar;19(3):634-45. doi: 10.1016/j.cellsig.2006.08.014. Epub 2006 Aug 30.
18	FGF21 Levels in Pheochromocytoma/Functional Paraganglioma.Cancers (Basel). 2019 Apr 5;11(4):485. doi: 10.3390/cancers11040485.
19	Virus-Mediated Overexpression of ETS-1 in the Ventral Hippocampus Counteracts Depression-Like Behaviors in Rats.Neurosci Bull. 2019 Dec;35(6):1035-1044. doi: 10.1007/s12264-019-00412-6. Epub 2019 Jul 20.
20	Transfection of PC12 cells with the human GAP-43 gene: effects on neurite outgrowth and regeneration.Brain Res Mol Brain Res. 1990 Jan;7(1):39-44. doi: 10.1016/0169-328x(90)90071-k.
21	Human pheochromocytomas, but not adrenal medulla, express glucagon-receptor gene and possess an in vitro secretory response to glucagon.Peptides. 2001 Apr;22(4):597-600. doi: 10.1016/s0196-9781(01)00369-2.
22	Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15879-84. doi: 10.1073/pnas.0907843106. Epub 2009 Aug 27.
23	Ghrelin localization in the medulla of rat and human adrenal gland and in pheochromocytomas.Histol Histopathol. 2008 Jan;23(1):57-65. doi: 10.14670/HH-23.57.
24	Human pheochromocytomas express orexin receptor type 2 gene and display an in vitro secretory response to orexins A and B.J Clin Endocrinol Metab. 2001 Oct;86(10):4818-21. doi: 10.1210/jcem.86.10.7929.
25	Overexpression of 17-hydroxysteroid dehydrogenase type 10 increases pheochromocytoma cell growth and resistance to cell death.BMC Cancer. 2015 Mar 22;15:166. doi: 10.1186/s12885-015-1173-5.
26	Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
27	Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas.J Clin Endocrinol Metab. 2012 Apr;97(4):1311-9. doi: 10.1210/jc.2011-2885. Epub 2012 Jan 25.
28	Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.J Mol Endocrinol. 2012 Feb 6;48(2):115-27. doi: 10.1530/JME-11-0077. Print 2012 Apr.
29	Multiple endocrine neoplasias: advances and challenges for the future.J Intern Med. 2009 Jul;266(1):1-4. doi: 10.1111/j.1365-2796.2009.02108.x.
30	Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy.J Clin Endocrinol Metab. 2007 Dec;92(12):4865-72. doi: 10.1210/jc.2007-1253. Epub 2007 Sep 18.
31	Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1.J Clin Endocrinol Metab. 2007 Jul;92(7):2784-92. doi: 10.1210/jc.2006-2833. Epub 2007 Apr 10.
32	Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis.Cancer Res. 2011 May 15;71(10):3669-75. doi: 10.1158/0008-5472.CAN-10-3962. Epub 2011 Mar 28.
33	The RET C611Y mutation causes MEN 2A and associated cutaneous.Endocr Connect. 2018 Sep 1;7(9):998-1005. doi: 10.1530/EC-18-0220.
34	6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.J Clin Endocrinol Metab. 2010 Jun;95(6):2800-10. doi: 10.1210/jc.2009-2352. Epub 2010 Apr 6.
35	Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine.Cancers (Basel). 2019 Jul 20;11(7):1018. doi: 10.3390/cancers11071018.
36	Imaging Features of Succinate Dehydrogenase-deficient Pheochromocytoma-Paraganglioma Syndromes.Radiographics. 2019 Sep-Oct;39(5):1393-1410. doi: 10.1148/rg.2019180151.
37	Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas.J Clin Endocrinol Metab. 1995 Jun;80(6):1837-44. doi: 10.1210/jcem.80.6.7775631.
38	Integrative analysis of neuroblastoma and pheochromocytoma genomics data.BMC Med Genomics. 2012 Oct 29;5:48. doi: 10.1186/1755-8794-5-48.
39	ERK5 induces ankrd1 for catecholamine biosynthesis and homeostasis in adrenal medullary cells.Cell Signal. 2016 Mar;28(3):177-189. doi: 10.1016/j.cellsig.2015.12.016. Epub 2015 Dec 29.
40	Origins and early development of the concept that brown adipose tissue thermogenesis is linked to energy balance and obesity.Biochimie. 2017 Mar;134:62-70. doi: 10.1016/j.biochi.2016.09.007. Epub 2016 Sep 10.
41	Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism.J Clin Endocrinol Metab. 2009 Feb;94(2):684-90. doi: 10.1210/jc.2008-1131. Epub 2008 Nov 11.
42	Expression of mRNA for PACAP and its receptors in intra- and extra-adrenal human pheochromocytomas and their relationship to catecholamine synthesis.Regul Pept. 2003 Feb 28;110(3):213-7. doi: 10.1016/s0167-0115(02)00209-4.
43	Adrenomedullin in heart failure: pathophysiology and therapeutic application.Eur J Heart Fail. 2019 Feb;21(2):163-171. doi: 10.1002/ejhf.1366. Epub 2018 Dec 28.
44	SNAP-25 Contributes to Neuropathic Pain by Regulation of VGLuT2 Expression in Rats.Neuroscience. 2019 Dec 15;423:86-97. doi: 10.1016/j.neuroscience.2019.10.007. Epub 2019 Nov 6.
45	RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family.PLoS One. 2011;6(5):e20353. doi: 10.1371/journal.pone.0020353. Epub 2011 May 31.
46	Gene expression profiling of rat pheochromocytoma.Ann N Y Acad Sci. 2006 Aug;1073:290-9. doi: 10.1196/annals.1353.033.
47	Secretin receptor promotes the proliferation of endocrine tumor cells via the PI3K/AKT pathway.Mol Endocrinol. 2012 Aug;26(8):1394-405. doi: 10.1210/me.2012-1055. Epub 2012 Jun 12.
48	Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
49	A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2(V617F) positive polycythemia vera: a case report.BMC Cancer. 2018 Mar 13;18(1):286. doi: 10.1186/s12885-018-4127-x.
50	Expression of adiponectin receptors 1 and 2 and the leptin receptor in human adrenal tumors.Arch Med Sci. 2019 Sep;15(5):1254-1260. doi: 10.5114/aoms.2018.76142. Epub 2018 Jun 1.
51	Cdc42 and Rac1 activity is reduced in human pheochromocytoma and correlates with FARP1 and ARHGEF1 expression.Endocr Relat Cancer. 2016 Apr;23(4):281-93. doi: 10.1530/ERC-15-0502. Epub 2016 Feb 24.
52	Tissue-specific expression of human achaete-scute homologue-1 in neuroendocrine tumors: transcriptional regulation by dual inhibitory regions.Cell Growth Differ. 1997 Jun;8(6):677-86.
53	Evaluation in humans of ELF-EMF exposure on chromogranin A, a marker of neuroendocrine tumors and stress.Chronobiol Int. 2020 Jan;37(1):60-67. doi: 10.1080/07420528.2019.1683857. Epub 2019 Nov 4.
54	Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior.Am J Surg Pathol. 2019 Mar;43(3):409-421. doi: 10.1097/PAS.0000000000001190.
55	65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma.Endocr Relat Cancer. 2018 Aug;25(8):T201-T219. doi: 10.1530/ERC-18-0085. Epub 2018 May 24.
56	Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas.J Clin Endocrinol Metab. 2018 Jan 1;103(1):46-55. doi: 10.1210/jc.2017-01314.
57	NAP Protects against Tau Hyperphosphorylation Through GSK3.Curr Pharm Des. 2018;24(33):3868-3877. doi: 10.2174/1381612824666181112105954.
58	Overexpression of the human ubiquitin E3 ligase CUL4A alleviates hypoxia-reoxygenation injury in pheochromocytoma (PC12) cells.Biochem Biophys Res Commun. 2011 Dec 16;416(3-4):403-8. doi: 10.1016/j.bbrc.2011.11.054. Epub 2011 Nov 19.
59	ARHI is a novel epigenetic silenced tumor suppressor in sporadic pheochromocytoma.Oncotarget. 2017 Sep 21;8(49):86325-86338. doi: 10.18632/oncotarget.21149. eCollection 2017 Oct 17.
60	Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas.Am J Hum Genet. 2019 Apr 4;104(4):651-664. doi: 10.1016/j.ajhg.2019.02.017. Epub 2019 Mar 28.
61	Expression of the von Hippel-Lindau-binding protein-1 (Vbp1) in fetal and adult mouse tissues.Hum Mol Genet. 1999 Feb;8(2):229-36. doi: 10.1093/hmg/8.2.229.
62	Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma.Endocr Relat Cancer. 2008 Sep;15(3):777-86. doi: 10.1677/ERC-08-0072. Epub 2008 May 22.
63	Tissue-specific high-level expression of human endogenous retrovirus-R in the human adrenal cortex.Pathobiology. 1998;66(5):209-15. doi: 10.1159/000028025.
64	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.Genet Med. 2019 Mar;21(3):705-717. doi: 10.1038/s41436-018-0106-5. Epub 2018 Jul 27.
65	Protein interactions with the glucose transporter binding protein GLUT1CBP that provide a link between GLUT1 and the cytoskeleton.Mol Biol Cell. 1999 Apr;10(4):819-32. doi: 10.1091/mbc.10.4.819.
66	Overexpression of the gene product of ocular albinism 1 (GPR143/OA1) but not its mutant forms inhibits neurite outgrowth in PC12cells.J Pharmacol Sci. 2019 Sep;141(1):41-48. doi: 10.1016/j.jphs.2019.09.002. Epub 2019 Sep 11.
67	Comprehensive Assessment of GPR68 Expression in Normal and Neoplastic Human Tissues Using a Novel Rabbit Monoclonal Antibody.Int J Mol Sci. 2019 Oct 23;20(21):5261. doi: 10.3390/ijms20215261.
68	Differential heparanase-1 expression in malignant and benign pheochromocytomas.J Surg Res. 2002 Nov;108(1):44-50. doi: 10.1006/jsre.2002.6451.
69	Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus.Lancet. 1991 May 4;337(8749):1052-4. doi: 10.1016/0140-6736(91)91705-y.
70	ISL1 is upregulated in breast cancer and promotes cell proliferation, invasion, and angiogenesis.Onco Targets Ther. 2018 Feb 14;11:781-789. doi: 10.2147/OTT.S144241. eCollection 2018.
71	Master regulator analysis of paragangliomas carrying SDHx, VHL, or MAML3 genetic alterations.BMC Cancer. 2019 Jun 24;19(1):619. doi: 10.1186/s12885-019-5813-z.
72	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients.Genet Med. 2018 Dec;20(12):1652-1662. doi: 10.1038/s41436-018-0068-7. Epub 2018 Jul 16.
73	First report of concomitant pheochromocytoma and duodenal neuroendocrine tumour in a sporadic multiple endocrine neoplasia type 1.BMJ Case Rep. 2018 Sep 4;2018:bcr2017222947. doi: 10.1136/bcr-2017-222947.
74	Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma.Br J Cancer. 1996 Aug;74(3):339-41. doi: 10.1038/bjc.1996.363.
75	Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators.J Clin Endocrinol Metab. 2013 Jan;98(1):E162-73. doi: 10.1210/jc.2012-2975. Epub 2012 Nov 15.
76	Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes.Cancer Res. 1992 Feb 15;52(4):770-4.
77	Phaeochromocytoma/paraganglioma and adverse clinical outcomes in patients with neurofibromatosis-1.Endocr Connect. 2018 Aug 17;7(10):R254-9. doi: 10.1530/EC-18-0208. Online ahead of print.
78	Expression analysis of RET and the GDNF/GFRalpha-1 and NTN/GFRalpha-2 ligand complexes in pheochromocytomas and paragangliomas.Int J Mol Med. 2000 Oct;6(4):469-74. doi: 10.3892/ijmm.6.4.469.
79	Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.J Clin Endocrinol Metab. 2019 Nov 1;104(11):5673-5692. doi: 10.1210/jc.2018-01471.
80	Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility.Endocr Relat Cancer. 2010 Dec 21;18(1):73-83. doi: 10.1677/ERC-10-0113. Print 2011 Feb.
81	Preproenkephalin A-derived opioid peptides and mRNA of preproenkephalin A in human pheochromocytomas.Mol Cell Endocrinol. 1987 Jun;51(3):237-41. doi: 10.1016/0303-7207(87)90033-5.
82	Expression of PC2 and PC1/PC3 in human pheochromocytomas.Mol Cell Endocrinol. 1994 Mar;99(2):307-14. doi: 10.1016/0303-7207(94)90022-1.
83	Tumor suppressor gene ZAC/PLAGL1: altered expression and loss of the nonimprinted allele in pheochromocytomas.Cancer Genet. 2011 Jul;204(7):398-404. doi: 10.1016/j.cancergen.2011.07.002.
84	Expression of melanin-concentrating hormone receptor messenger ribonucleic acid in tumor tissues of pheochromocytoma, ganglioneuroblastoma, and neuroblastoma.J Clin Endocrinol Metab. 2001 Jan;86(1):369-74. doi: 10.1210/jcem.86.1.7158.
85	Deletions and altered expression of the RIZ1 tumour suppressor gene in 1p36 in pheochromocytomas and abdominal paragangliomas.Int J Oncol. 2005 May;26(5):1385-91.
86	Leukocyte common-antigen-related tyrosine phosphatase receptor: altered expression of mRNA and protein in the New England Deaconess Hospital rat line exhibiting spontaneous pheochromocytoma.Carcinogenesis. 2000 Feb;21(2):125-31. doi: 10.1093/carcin/21.2.125.
87	The human Rab genes encode a family of GTP-binding proteins related to yeast YPT1 and SEC4 products involved in secretion.J Biol Chem. 1989 Jul 25;264(21):12394-401.
88	The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma.Endocr Relat Cancer. 2007 Mar;14(1):125-34. doi: 10.1677/ERC-06-0031.
89	The mutation for medullary thyroid carcinoma with parathyroid tumors (MTC with PTs) is closely linked to the centromeric region of chromosome 10.Am J Hum Genet. 1990 Dec;47(6):946-51.
90	Nrdp1 Increases Ischemia Induced Primary Rat Cerebral Cortical Neurons and Pheochromocytoma Cells Apoptosis Via Downregulation of HIF-1 Protein.Front Cell Neurosci. 2017 Sep 20;11:293. doi: 10.3389/fncel.2017.00293. eCollection 2017.
91	RSUME inhibits VHL and regulates its tumor suppressor function.Oncogene. 2015 Sep 10;34(37):4855-66. doi: 10.1038/onc.2014.407. Epub 2014 Dec 15.
92	Clinical Aspects of SDHA-Related Pheochromocytoma and Paraganglioma: A Nationwide Study. J Clin Endocrinol Metab. 2018 Feb 1;103(2):438-445. doi: 10.1210/jc.2017-01762.
93	Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.JAMA Oncol. 2017 Sep 1;3(9):1204-1212. doi: 10.1001/jamaoncol.2017.0223.
94	Analysis of SDHAF3 in familial and sporadic pheochromocytoma and paraganglioma.BMC Cancer. 2017 Jul 24;17(1):497. doi: 10.1186/s12885-017-3486-z.
95	Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association.Virchows Arch. 2015 Jun;466(6):727-32. doi: 10.1007/s00428-015-1755-2. Epub 2015 Mar 24.
96	Analysis of multiple molecular changes in human endocrine tumours.Surg Oncol. 1994 Jun;3(3):153-9. doi: 10.1016/0960-7404(94)90044-2.
97	Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas.Neuropeptides. 1999 Apr;33(2):159-63. doi: 10.1054/npep.1999.0012.